EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prediction of metachronous advanced colorectal neoplasia by KRAS mutation in polyps

Alejandro Martínez-Roca iD, Joaquín Cubiella iD, Anabel García-Heredia, David Guill-Berbegal, Sandra Baile-Maxía iD, Carolina Mangas-Sanjuán, Noelia Sala-Miquel, Lucía Madero-Velazquez, Cristina Alenda, Pedro Zapater, Clara González-Núñez, Agueda Iglesias-Gómez und 12 weitere

United European Gastroenterology Journal · 2024

DOI: 10.1002/ueg2.12667 ↗

Kurz gefasst

Fachartikel in der Zeitschrift United European Gastroenterology Journal, 2024. Verfasst von Alejandro Martínez-Roca und 23 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Medicina Digestiva, Instituto de Investigación Sanitaria ISABIAL, Hospital General Universitario Dr. Balmis, Alicante, Spain. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Mutation, Colonic Polyps. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III, Gonzalo Miño Grant Asociación Española de Gastroenterología 2016 and 2022, Fundación SEED Grant 2018.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The potential of molecular markers in the removed polys as reliable predictors of metachronous lesions is still uncertain.

Aim

Our aim was to evaluate the role of somatic mutations in KRAS in polyps of patients with high‐risk adenomas to predict the risk of advanced polyps or colorectal cancer (CRC) within 3 years.

Methods

A total of 518 patients were prospectively enrolled. The included patients had adenomas ≥10 mm, high‐grade dysplasia, villous component or ≥3 more adenomas at baseline and were scheduled to undergo surveillance colonoscopy at 3 years ± 6 months. Somatic KRAS mutation was performed on 1189 polyps collected from these patients. At surveillance, advanced lesions were defined as adenomas with a size of ≥10 mm. High‐grade dysplasia or villous component, serrated polyps ≥10 mm or with dysplasia or CRC.

Results

At baseline, 81 patients (15.6%) had KRAS mutations in at least one polyp. Patients with KRAS mutated polyps had more frequent villous histological lesions and size ≥20 mm. In the multivariate analysis, adjusted for age and sex, only age (odds ratios [OR], 1.06; 95% confidence interval [CI], 1.02–1.09; p < 0.001), ≥5 adenomas (OR, 3.92; 95% CI, 1.96–7.82), and KRAS mutation (OR, 2.54; 95% CI, 1.48–4.34; p < 0.01) were independently associated with the development of advanced lesions at surveillance.

Conclusions

Our results show that, in patients with high‐risk adenomas, the presence of somatic mutations in KRAS is an independent risk factor for the development of advanced metachronous polyps.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsProto-Oncogene Proteins p21(ras)MutationColonic PolypsColonoscopyAdenomaHumansMaleFemaleMiddle AgedAgedProspective StudiesNeoplasms, Second PrimaryRisk Factors

Stichwörter der Autor:innen

KRAS mutationcolonic polypscolorectal cancersurveillancetumor markers

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Servicio de Medicina Digestiva, Instituto de Investigación Sanitaria ISABIAL, Hospital General Universitario Dr. Balmis, Alicante, Spain.
  • Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain.
  • Department of Gastroenterology, Research Group in Gastrointestinal Oncology-Ourense, CIBEREHD, Hospital Universitario de Ourense, Ourense, Spain.
  • Pathology Department, Alicante Institute for Health and Biomedical Research (ISABIAL), Dr. Balmis General University Hospital, Alicante, Spain.
  • Clinical Pharmacology Department, Alicante Institute for Health and Biomedical Research (ISABIAL), Dr. Balmis General University Hospital, Alicante, Spain.
  • Department of Pathology, Hospital Universitario de Ourense, Ourense, Spain.

ORCID-Profile: Alejandro Martínez-Roca, Joaquín Cubiella, Sandra Baile-Maxía, Monika Ferlitsch, Rodrigo Jover

Förderung

  • Instituto de Salud Carlos III
  • Gonzalo Miño Grant Asociación Española de Gastroenterología 2016 and 2022
  • Fundación SEED Grant 2018

Zitieren

APA

Martínez-Roca, A., Cubiella, J., García-Heredia, A., Guill-Berbegal, D., Baile-Maxía, S., Mangas-Sanjuán, C., Sala-Miquel, N., Madero-Velazquez, L., Alenda, C., Zapater, P., González-Núñez, C., Iglesias-Gómez, A., Codesido-Prado, L., Díez-Martín, A., Kaminski, M. F., Erichsen, R., Adami, H. O., Ferlitsch, M., Pellisé, M., …, & EPoS Study Group (2024). Prediction of metachronous advanced colorectal neoplasia by KRAS mutation in polyps. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12667

Vancouver

Martínez-Roca A, Cubiella J, García-Heredia A, Guill-Berbegal D, Baile-Maxía S, Mangas-Sanjuán C, et al. Prediction of metachronous advanced colorectal neoplasia by KRAS mutation in polyps. United European Gastroenterology Journal. 2024. doi:10.1002/ueg2.12667

BibTeX
@article{MartnezRoca2024,
  author = {Martínez-Roca, Alejandro and Cubiella, Joaquín and García-Heredia, Anabel and Guill-Berbegal, David and Baile-Maxía, Sandra and Mangas-Sanjuán, Carolina and Sala-Miquel, Noelia and Madero-Velazquez, Lucía and Alenda, Cristina and Zapater, Pedro and González-Núñez, Clara and Iglesias-Gómez, Agueda and Codesido-Prado, Laura and Díez-Martín, Astrid and Kaminski, Michal F and Erichsen, Rune and Adami, Hans-Olov and Ferlitsch, Monika and Pellisé, María and Holme, Øyvind and Dekker, Evelien and Bretthauer, Michael and Jover, Rodrigo and EPoS Study Group, EPoS Study Group},
  title = {Prediction of metachronous advanced colorectal neoplasia by KRAS mutation in polyps},
  journal = {United European Gastroenterology Journal},
  year = {2024},
  doi = {10.1002/ueg2.12667}
}
Kostenlos starten →